{"product_id":"supn-five-forces","title":"(SUPN) Supernus Pharmaceuticals, Inc. Porters Five Forces Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Supernus Pharmaceuticals, Inc. Porter's Five Forces Analysis helps you assess industry competition, supplier and buyer power, substitutes, and the threat of new entrants. The page already shows a real preview of the report content, so you can see exactly what’s included before buying. Purchase the full version for the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSuppliers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty API dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals, Inc. depends on specialty active pharmaceutical ingredients for CNS therapies and extended-release products, and those inputs usually come from a small pool of qualified vendors. Switching suppliers can take many months because FDA validation, stability work, and quality checks must be redone, so supplier leverage stays high. That risk is sharper when one API supports multiple products and delays can hit revenue timing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturing reliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals, Inc. relies on external manufacturing and packaging partners for parts of its portfolio, so qualified CDMOs can hold real pricing power, especially for complex dosage forms and device combos. If a partner hits capacity limits or a tech-transfer setback, Supernus Pharmaceuticals, Inc. can face higher costs and product delays. That makes supplier leverage a clear, but manageable, risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality and regulatory hurdles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFDA cGMP rules under 21 CFR Parts 210\/211 mean only a small set of qualified API and excipient vendors can supply Supernus Pharmaceuticals, Inc. That shrinks the supplier pool and gives approved vendors leverage on price and lead times. Each new source also adds audit, validation, and re-qualification work, which can raise costs and slow supply changes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDevice and component vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals, Inc. faces moderate-to-high supplier power where SPN-830 and other specialty therapies need proprietary delivery parts, containers, and device inputs that are harder to swap than commodity materials. That raises vendor leverage when design is tightly integrated and validation is costly. In 2025, Supernus Pharmaceuticals, Inc. reported about $650 million in revenue, so any device disruption can hit launch timing and margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized inputs are less interchangeable.\u003c\/li\u003e\n\u003cli\u003eProprietary designs strengthen suppliers.\u003c\/li\u003e\n\u003cli\u003eDelays can slow approvals and supply.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eModerate switching costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOnce a supplier is validated, Supernus Pharmaceuticals, Inc. may face expensive and slow switching costs because reformulation, revalidation, and stability testing can take 3-12 months and delay launches. That lifts supplier power, especially for drug-specific inputs, but Supernus can soften it with multi-sourcing and tighter inventory planning. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eValidated suppliers are hard to replace.\u003c\/li\u003e\n\u003cli\u003eTesting can delay launches by months.\u003c\/li\u003e\n\u003cli\u003eMulti-sourcing reduces dependency risk.\u003c\/li\u003e\n\u003cli\u003eInventory buffers help absorb disruptions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupernus Faces Supplier Power Risks From Narrow API and CDMO Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals, Inc. faces moderate-to-high supplier power because specialty APIs, CDMO capacity, and validated device parts come from a narrow vendor base. Switching can take months, so suppliers can press on price and lead times. With about $650 million in 2025 revenue, even small supply shocks can affect margins and launch timing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSupplier power driver\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualified API vendors\u003c\/td\u003e\n\u003ctd\u003eLimited pool\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching cost\u003c\/td\u003e\n\u003ctd\u003e3-12 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 revenue\u003c\/td\u003e\n\u003ctd\u003eAbout $650 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Supernus Pharmaceuticals, Inc.’s competitive pressures, supplier and buyer power, entry barriers, and substitute threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA quick, one-page view of Supernus’s five forces—so you can spot competitive pressure and act faster.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear source trail for Supernus Pharmaceuticals, Inc., boosting trust and making key assumptions easier to verify, update, and defend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesaler concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals sells through a concentrated network of wholesalers and specialty pharmacies, so a small group of intermediaries can press on service levels, delivery terms, and inventory targets. That channel mix gives them leverage on working capital and logistics, especially when they can delay buys or ask for tighter fill rates.\u003c\/p\u003e\n\u003cp\u003eFor a CNS drug maker with a focused portfolio, that means customer power is moderate, not high, but still meaningful at the distribution layer.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer and PBM pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCustomer power is high for Supernus Pharmaceuticals, Inc. because about 80% of U.S. prescriptions run through the top 3 PBMs, and payer access can decide volume. PBMs and insurers can demand rebates, discounts, and prior-authorization rules, so formulary wins often matter more than end-patient demand. That pressure can trim net pricing even when prescription demand is stable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice sensitivity from generics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrice pressure stays high because generics account for about 90% of U.S. prescriptions but only 17% of drug spending, so payers push harder on net price in CNS. When clinical separation is thin, buyers can shift to low-cost, long-used alternatives fast. Supernus has to defend value with proven efficacy, simpler dosing, and branded protection.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePhysician and patient influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePhysicians drive Supernus Pharmaceuticals, Inc. demand, but payer coverage can override that choice; in the U.S., PBMs and health plans manage access for most prescriptions, so reimbursement often decides the winner. Patients may stick with branded drugs if they improve adherence or tolerability, yet higher copays can still push switches or delays. So buyer power is real, but it works through coverage rules, not direct price talks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDoctors steer the script.\u003c\/li\u003e\n\u003cli\u003ePayers control access.\u003c\/li\u003e\n\u003cli\u003eCopays still move demand.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFormulary access dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals, Inc. depends on formulary access to scale Qelbree and Parkinson’s therapies; without preferred placement, prescriptions can drop fast. In 2025, net product sales were about $600 million, so even small access losses can hit revenue. That dependence raises customer bargaining power and forces Supernus to keep contracting tight and back its brands with stronger clinical evidence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroad formulary access drives volume.\u003c\/li\u003e\n\u003cli\u003eLosing placement cuts prescriptions fast.\u003c\/li\u003e\n\u003cli\u003eBuyer power stays high.\u003c\/li\u003e\n\u003cli\u003eEvidence and rebates matter more.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupernus Faces Strong Payer Power as Formulary Access Drives Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomer power is moderate to high for Supernus Pharmaceuticals, Inc. because payers and PBMs decide access for most U.S. prescriptions, and that can outweigh physician demand. In 2025, Supernus Pharmaceuticals, Inc. reported about $600 million in net product sales, so even small formulary shifts can move revenue. Price pressure stays firm when rebates, prior auth, and copay rules shape use.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product sales\u003c\/td\u003e\n\u003ctd\u003e~$600 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer power\u003c\/td\u003e\n\u003ctd\u003eModerate to high\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMain lever\u003c\/td\u003e\n\u003ctd\u003eFormulary access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eSupernus Pharmaceuticals, Inc. Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Supernus Pharmaceuticals, Inc. Porter's Five Forces Analysis you’ll receive after purchase—no placeholders, no mockups, just the finished document. It’s fully formatted and ready to use the moment your payment is complete. What you see here is the same file you’ll download instantly, so you can buy with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRivalry Among Competitors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCNS market crowding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry in the CNS market is high because Supernus Pharmaceuticals, Inc. competes with branded, generic, and specialty pharma players across at least 4 big areas: neurology, psychiatry, epilepsy, and ADHD. That crowding raises pressure on launch speed, promotion spend, and line extensions, while Parkinson’s drugs add another fight for prescribers. In a market where several firms chase the same doctors and patients, price and differentiation matter a lot.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric competition pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals, Inc. faces heavy generic pressure because several products compete with low-cost older drugs and AB-rated copies, especially in CNS care. When patents weaken, pricing power drops fast; for example, generic topiramate and other legacy standards can undercut branded epilepsy and migraine therapies. Supernus protects revenue with formulation IP, line extensions, and payer access, but that defense is strongest only while exclusivity holds.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBranded differentiation battles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFor Qelbree, GOCOVRI, APOKYN, and XADAGO, Supernus Pharmaceuticals, Inc. competes on efficacy, tolerability, and convenience, but that edge can erode fast if rivals publish better studies or win stronger reimbursement. In 2025, branded CNS drugs still faced heavy payer pressure, so marketing and medical affairs stayed central to defend differentiation and support prescribing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline race\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLate-stage CNS drug development is a costly sprint, with Phase 3 programs often running into tens of millions of dollars and years of work. Supernus Pharmaceuticals, Inc. faces rivals in ADHD, epilepsy, depression, and Parkinson’s, so speed to data, FDA wins, and clean launch execution can matter more than the science alone.\u003c\/p\u003e\n\u003cp\u003eIn 2025, Supernus Pharmaceuticals, Inc. remained tied to a crowded neuropsychiatry field where each delay can hand share to better-funded peers. The pipeline race is especially sharp in ADHD and epilepsy, where label scope, trial readouts, and payer access can shift value fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase 3 CNS trials are capital heavy.\u003c\/li\u003e\n\u003cli\u003eCompetitors span ADHD, epilepsy, depression, Parkinson’s.\u003c\/li\u003e\n\u003cli\u003eFast data and FDA success drive edge.\u003c\/li\u003e\n\u003cli\u003eLaunch execution can decide market share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNiche indication rivalry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals, Inc. faces high rivalry even in niche areas like dystonia, sialorrhea, and off episodes, because each approved therapy can win a large share of a small patient pool. In 2025, the company reported about $650 million in revenue, so losing even one product or label matters. Focused rivals also target rare neurology and movement-disorder markets, keeping pricing and launch pressure intense.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eSmall markets still draw focused rivals.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eOne approved drug can dominate share.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e2025 revenue was about $650 million.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupernus Faces Intense CNS Rivalry as 2025 Revenue Hits $650M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry for Supernus Pharmaceuticals, Inc. stays high because its CNS portfolio fights branded, generic, and specialty rivals across ADHD, epilepsy, Parkinson’s, and related neurology markets. In 2025, Supernus Pharmaceuticals, Inc. reported about $650 million in revenue, so share loss on even one product can move results. Pricing, payer access, and launch speed all shape who wins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey point\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eAbout $650 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMain rivalry\u003c\/td\u003e\n\u003ctd\u003eBranded, generic, specialty CNS rivals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSubstitutes Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlternative drug classes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients and physicians can switch among many drug classes for epilepsy, ADHD, depression, and Parkinson’s disease, so Supernus Pharmaceuticals, Inc. faces real substitution risk. For ADHD alone, stimulants and non-stimulants can replace each other if tolerability or coverage is weak, and in epilepsy and depression, broad class choices make switching easy. This keeps pricing power limited and raises the chance of share loss if one brand slips.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric and off-patent options\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOlder therapies and generics can replace Supernus Pharmaceuticals, Inc. branded drugs when clinical gains are small. In U.S. retail pharmacy, generics made up about 90% of prescriptions by volume in 2025, so low-price options stay a strong substitute threat. That matters in chronic CNS care, where physicians know older standards well and often stick with them if outcomes look similar.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-drug interventions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBehavioral therapy, device-based care, physical therapy, and lifestyle changes can trim drug use, especially in ADHD, depression, and some Parkinson’s care. About 7 million U.S. children live with ADHD and about 1 million Americans have Parkinson’s, so even small shifts to non-drug care can hit prescription volumes. Still, these options usually complement, not replace, medicines, so Supernus Pharmaceuticals, Inc. faces a moderate threat from substitutes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCombination and adjunct therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCombination and adjunct therapy raises substitute risk because clinicians can swap from monotherapy to add-on or rescue treatment when symptoms break through. In epilepsy, about 3.4 million people in the U.S. live with the condition, and roughly 1 in 3 still have uncontrolled seizures, so prescribers often change regimens fast. Supernus must show clear outcome gains to keep share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSwitching costs stay low\u003c\/li\u003e\n\u003cli\u003eAdd-on use weakens loyalty\u003c\/li\u003e\n\u003cli\u003eProof of better outcomes matters\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFormulation switching\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFormulation switching is a real threat for Supernus Pharmaceuticals, Inc. because extended-release and other delivery formats can replace immediate-release or simple oral dosing when they cut pill burden and improve adherence. In CNS therapy, even small convenience gains can shift patients and prescribers to a rival product. That risk matters in markets where missed doses can weaken outcomes and loyalty.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eER formats can replace simpler oral pills\u003c\/li\u003e\n\u003cli\u003eBetter dosing can lift adherence and switching\u003c\/li\u003e\n\u003cli\u003eCNS care makes convenience a key driver\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupernus Faces Moderate-to-High Substitute Pressure in CNS Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of substitutes for Supernus Pharmaceuticals, Inc. is moderate to high because CNS care has many drug and non-drug options, and switching costs are low. U.S. generics made up about 90% of prescriptions by volume in 2025, which keeps price pressure intense. In ADHD, epilepsy, and Parkinson’s disease, physicians can also shift to older drugs, add-on therapy, or behavioral care if results soften.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSubstitute\u003c\/th\u003e\n\u003cth\u003e2025\/2026 data\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics\u003c\/td\u003e\n\u003ctd\u003e~90% of U.S. Rx volume\u003c\/td\u003e\n\u003ctd\u003eHigh price pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eADHD \/ epilepsy options\u003c\/td\u003e\n\u003ctd\u003eBroad class overlap\u003c\/td\u003e\n\u003ctd\u003eEasy switching\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-drug care\u003c\/td\u003e\n\u003ctd\u003eBehavioral, device, lifestyle\u003c\/td\u003e\n\u003ctd\u003ePartial replacement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEntrants Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh FDA barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh FDA barriers keep Supernus Pharmaceuticals, Inc. protected because CNS drugs often need 10+ years of trials, safety data, and review before launch, with development costs commonly topping $1B. In 2024, the FDA approved just 50 novel drugs, showing how few candidates survive the process. Most entrants fail before commercialization, so matching Supernus in established CNS markets is hard.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent and exclusivity walls\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals, Inc. and its rivals rely on patent, FDA exclusivity, and formulation shields to protect products; patents often last 20 years from filing, and generic challengers can also face 180-day exclusivity fights. New entrants usually must wait for expiry or design around claims, which slows entry on marketed brands. That makes the near-term threat low for protected products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital intensive launch path\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBuilding a CNS franchise is expensive: Phase 3 trials can cost $20 million to $100 million, and a commercial launch also needs manufacturing, medical affairs, and a sales force. For a small or mid-sized biotech, that capital load is hard to fund. It keeps many new entrants out of the market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommercial access complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCommercial access is a high hurdle for Supernus Pharmaceuticals, Inc. even after FDA approval, because a new drug still has to win formulary placement, payer coverage, pharmacy stocking, and prescriber trust. That slows uptake and raises launch costs, especially against branded rivals with established rebate deals and patient support. The gatekeeping power of payers makes entry expensive and adoption slow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFormulary wins can lag approval.\u003c\/li\u003e\n\u003cli\u003ePayers control patient access.\u003c\/li\u003e\n\u003cli\u003eEstablished brands hold an edge.\u003c\/li\u003e\n\u003cli\u003eAccess costs lift entry barriers.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiotech startup pipeline risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiotech startup pipeline risk is real for Supernus Pharmaceuticals, Inc., but it is usually moderate to low. Even with high clinical, regulatory, and capital barriers, a startup can break in with a novel mechanism or a device-drug combo, and licensing can speed that path if the data look strong.\u003c\/p\u003e\n\u003cp\u003eFDA approvals show why the threat stays alive: 2024 had 50 novel drug approvals, but most still came after years of costly trials and heavy financing needs. That keeps entry hard for new biotech firms, so the force is weaker than buyer or rival pressure for Supernus Pharmaceuticals, Inc.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh barriers slow most startups.\u003c\/li\u003e\n\u003cli\u003eNovel assets can still enter.\u003c\/li\u003e\n\u003cli\u003eLicensing can shorten launch time.\u003c\/li\u003e\n\u003cli\u003eThreat stays moderate to low.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupernus Faces Low to Moderate Threat from New Entrants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of new entrants for Supernus Pharmaceuticals, Inc. stays low to moderate. CNS drug entry still needs years of trials, FDA review, and heavy capital, while the FDA approved only 50 novel drugs in 2024.\u003c\/p\u003e\n\u003cp\u003ePatent, exclusivity, and payer hurdles also slow launch, so even approved rivals face weak access at first. New entrants can still appear through licensing or a novel mechanism, but that is rare.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA review\u003c\/td\u003e\n\u003ctd\u003eLong, costly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovel drug approvals\u003c\/td\u003e\n\u003ctd\u003e50 in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital need\u003c\/td\u003e\n\u003ctd\u003eVery high\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall threat\u003c\/td\u003e\n\u003ctd\u003eLow to moderate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235087655177,"sku":"supn-five-forces","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/supn-five-forces.webp?v=1785732893","url":"https:\/\/dcfanalyst.com\/products\/supn-five-forces","provider":"DCF Analyst","version":"1.0","type":"link"}